FREE PhD study and funding virtual fair REGISTER NOW FREE PhD study and funding virtual fair REGISTER NOW

Re-purposing Cefepime / Sulbactam as a Precision Treatment for Gram-negative Infections


   Blizard Institute

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr D Wareham, Dr O Marches, Dr J Standing  No more applications being accepted  Funded PhD Project (UK Students Only)

About the Project

Applications are invited from graduates in Microbiology or other relevant biomedical sciences (First or Upper Second) to work with Antimicrobial Research UK (ANTRUK) on Re-purposing β-lactam Combination Therapies as a Precision Treatment for Gram-negative Infections. This 3 year studentship will commence in September 2022 and be based at the Blizard Institute within the School of Medicine and Dentistry.

We have identified a potent synergistic antimicrobial interaction when cefepime is combined with sulbactam against multi-drug resistant Acinetobacter spp and Enterobacterales strains in-vitro (Wareham et, al 2020). Activity of the combination has been confirmed in a national surveillance study (MUTATE) conducted by ANTRUK using a disc diffusion assay developed for rapid susceptibility testing. A pharmacodynamic hollow-fibre dose ranging study is underway (Prof J Standing, UCL Precision Medicine) to determine the optimal formulation for the treatment of MDR Gram-negative infections. Progression of cefepime / sulbactam towards clinical use and a licensed indication requires further studies to inform on dosing, comparative activity, resistance potential, toxicology and clinical efficacy. These issues will be addressed as part of the experimental work to be undertaken in this 3-year PhD studentship.

Interviews to be held on Monday 5th September 2022

To apply, please follow this link: https://mysis.qmul.ac.uk/urd/sits.urd/run/siw_ipp_lgn.login?process=siw_ipp_app&code1=RFQM-W1XF-09&code2=0013


Funding Notes

This 3 year PhD studentship is funded by Queen Mary, University of London in collaboration with Antimicrobial Research UK and comes with a tax-free stipend of £18,489.67 per annum (in the first year). It is open to UK Nationals, EEA/Swiss migrant workers and non-UK nationals with indefinite leave to remain in the UK who will have three years ordinary residence in the EU prior to the start of the studentship. University tuition fees (at UK/EU levels) will be met by the funding body. The project is open to overseas applicants able to self-fund tuition and bench fees.

References

Wareham DW, Momin MHFA, Phee LM, Hornsey M, Standing JF. Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy. 2019 Oct 16. pii: dkz420. doi: 10.1093/jac/dkz420

How good is research at Queen Mary University of London in Clinical Medicine?


Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.

PhD saved successfully
View saved PhDs